Delegation visit ahead of patent law report.
India had been engaged in a contentious battle with the US over the issue, especially in the pharmaceutical sector.
Special 301 Report expresses concern over weak IPR laws, to conduct reviews.
A certain segment of the US pharma industry have become vocal about Indian policies on domestic content requirements and IPR.
Flaring of tempers comes atop much simmering trouble on clashing views; these stands might now get frozen.
© 2026 Rediff.com - Investor Information - Advertise with us - Disclaimer - Privacy Policy - Sitemap - Feedback - About us - Terms of use - Grievances